 Clinical trials have been essential tools for evaluating the safety and effectiveness of new drugs, medical devices, and health system interventions. During the COVID-19 pandemic, social distancing measures have posed challenges to traditional models of clinical trial conduct, requiring researchers to adapt quickly by implementing virtual visits and other similar methods. Despite this transition, clinical research has continued due to the quick adaptation of research teams. In the future, it is expected that a hybrid approach combining remote activities with in-person activities will become more commonplace for clinical trials. This hybrid approach will allow for remote activities to be implemented when feasible, while still maintaining in-person activities as needed. This article was authored by Tammy L. Laucs, Claire Tyson, David Dore, and others.